Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04746209 | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | recruiting | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT05040555 | R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden | recruiting | N/A | 64 | oubai, MD/PhDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03787056 |
| Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients(ONCOPRO) |
| recruiting |
| N/A |
| 410 |
| Hospices Civils de LyonOTHER |
| 1 |
| Jul 16, 2021 |
| clinicaltrials |
| NCT03869619 | REal World Data in LYmphoma and Survival in Adults(REALYSA) | recruiting | — | 6,000 | Hospices Civils de LyonOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT04913103 | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL(CLSGMCLPOLA) | not yet recruiting | Phase 2 | 21 | Czech Lymphoma Study GroupOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT03709719 | Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia(GRAALL-QUEST) | active not recruiting | Phase 2 | 95 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03606577 | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients(IFM 2018-04) | active not recruiting | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04856137 | A Phase I/II Study of Diffuse Large B-cell Lymphoma(DLBL) | not yet recruiting | Phase 1 / Phase 2 | 74 | National Health Research Institutes, TaiwanOTHER | 0 | Apr 23, 2021 | clinicaltrials |
| NCT04824950 | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)(CAMIL) | recruiting | N/A | 87 | Centre Henri BecquerelOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04771507 | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)(IbruOnOff) | recruiting | Phase 1 / Phase 2 | 50 | Jeanette LundinOTHER | 2 | Feb 25, 2021 | clinicaltrials |
| NCT04702932 | Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies(GEN-HEMO-INF) | not yet recruiting | — | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03356054 | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse(HOVON 136 NHL) | recruiting | Phase 1 / Phase 2 | 37 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04603872 | CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies | recruiting | Early Phase 1 | 120 | Zhejiang UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04595162 | A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | not yet recruiting | Phase 1 | 12 | Peking University Third HospitalOTHER | 0 | Oct 20, 2020 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04491721 | Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL | enrolling by invitation | — | 407 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04338386 | Detection and Pathogenesis of Novel Protein F | not yet recruiting | — | 100 | Wuhan Asia Heart HospitalOTHER | 0 | Apr 10, 2020 | clinicaltrials |
| NCT03815279 | A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)(iStopMM) | enrolling by invitation | Phase 2 | 80 | Landspitali University HospitalOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT04025450 | Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03980002 | A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL(BDHCLL001) | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT03966443 | Fluciclovine PET/CT in Multiple Myeloma Patients(FLUCIPET) | recruiting | — | 10 | Oslo University HospitalOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT03196414 | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | recruiting | Phase 3 | 406 | University of LeedsOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT02869555 | Institut Paoli Calmettes Multiple Myeloma Database | recruiting | — | 5,000 | Institut Paoli-CalmettesOTHER | 1 | Aug 17, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 17, 2021source: clinicaltrials